Among other detectors, the T2K neutrino experiment comprises three large time projection chambers segmented into over 124.000 electronics channels. The back-end electronics system is designed to ...distribute a reference clock to the front-end electronics, aggregate event data over seventy-two 2 Gbit/s optical links and format events that are sent via a standard PC to the global data acquisition system of the experiment. The core of this system is a set of 18 Data Concentrator Cards based on an inexpensive commercial Field Programmable Gate Array evaluation kit with specific add-ons. We describe the adaptations that were made to the original platform, and detail the design of the firmware and software running on the embedded PowerPC processor of the FPGA of a Data Concentrator Card. We show how the intrinsic parallelism and a mixed firmware and software implementation of the data reduction and acquisition tasks lead to a flexible system capable of extracting in real time meaningful information from the 2.5 GByte/s of raw event data produced by the front-end electronics at a nominal rate of 20 Hz.
The second phase of the T2K experiment is expected to start data taking in autumn 2022. An upgrade of the Near Detector (ND280) is under development and includes the construction of two new Time ...Projection Chambers called High-Angle TPC (HA-TPC). The two endplates of these TPCs will be paved with eight Micromegas type charge readout modules. The Micromegas detector charge amplification structure uses a resistive anode to spread the charges over several pads to improve the space point resolution. This innovative technique is combined with the bulk-Micromegas technology to compose the “Encapsulated Resistive Anode Micromegas” detector. A prototype has been designed, built and exposed to an electron beam at the DESY II test beam facility.
The data have been used to characterize the charge spreading and to produce its map. Spatial resolution better than 600 μm and energy resolution better than 9% are obtained for all incident angles. These performances fulfil the requirements for the upgrade of the ND280 TPC.
In this paper we describe the performance of a prototype of the High Angle Time Projection Chambers (HA-TPCs) that are being produced for the Near Detector (ND280) upgrade of the T2K experiment. The ...two HA-TPCs of ND280 will be instrumented with eight Encapsulated Resistive Anode Micromegas (ERAM) on each endplate, for a total of 32 ERAMs. This innovative technique allows the detection of the charge emitted by ionization electrons over several pads, improving the determination of the track position.
The TPC prototype has been equipped with the first ERAM module produced for T2K and with the HA-TPC readout electronics chain and it has been exposed to an electron beam at DESY in order to measure spatial and dE/dx resolution. In this paper we characterize the performances of the ERAM and, for the first time, we compare them with a newly developed simulation of the detector response.
Spatial resolution better than 800 μm and dE/dx resolution better than 10% are observed for all the incident angles and for all the drift distances of interest. All the main features of the data are correctly reproduced by the simulation and these performances fully fulfill the requirements for the HA-TPCs of T2K.
Among other detectors, the T2K neutrino experiment comprises three large time projection chambers segmented into over 124.000 electronics channels. The back-end electronics system is designed to ...distribute a reference clock to the front-end electronics, aggregate event data over seventy-two 2 Gbps optical links and format events that are sent via a standard PC to the global data acquisition system of the experiment. The core of this system is a set of 18 Data Concentrator Cards based on an inexpensive commercial Field Programmable Gate Array evaluation kit with specific add-ons. We describe the adaptations that were made to the original platform, and detail the design of the firmware and software running on the embedded PowerPC processor of the FPGA of a Data Concentrator Card. We show how the intrinsic parallelism and a mixed firmware and software implementation of the data reduction and acquisition tasks lead to a flexible system capable of extracting in real time meaningful information from the 2.5 GByte/s of raw event data produced by the front-end electronics at a nominal rate of 20 Hz.
In this paper we describe the performance of a prototype of the High Angle Time Projection Chambers (HA-TPCs) that are being produced for the Near Detector (ND280) upgrade of the T2K experiment. The ...two HA-TPCs of ND280 will be instrumented with eight Encapsulated Resistive Anode Micromegas (ERAM) on each endplate, thus constituting in total 32 ERAMs. This innovative technique allows the detection of the charge emitted by ionization electrons over several pads, improving the determination of the track position. The TPC prototype has been equipped with the first ERAM module produced for T2K and with the HA-TPC readout electronics chain and it has been exposed to the DESY Test Beam in order to measure spatial and dE/dx resolution. In this paper we characterize the performances of the ERAM and, for the first time, we compare them with a newly developed simulation of the detector response. Spatial resolution better than 800 \({\mu \rm m}\) and dE/dx resolution better than 10% are observed for all the incident angles and for all the drift distances of interest. All the main features of the data are correctly reproduced by the simulation and these performances fully fulfill the requirements for the HA-TPCs of T2K.
An upgrade of the near detector of the T2K long baseline neutrino oscillation experiment is currently being conducted. This upgrade will include two new Time Projection Chambers, each equipped with ...16 charge readout resistive Micromegas modules. A procedure to validate the performance of the detectors at different stages of production has been developed and implemented to ensure a proper and reliable operation of the detectors once installed. A dedicated X-ray test bench is used to characterize the detectors by scanning each pad individually and to precisely measure the uniformity of the gain and the deposited energy resolution over the pad plane. An energy resolution of about 10% is obtained. A detailed physical model has been developed to describe the charge dispersion phenomena in the resistive Micromegas anode. The detailed physical description includes initial ionization, electron drift, diffusion effects and the readout electronics effects. The model provides an excellent characterization of the charge spreading of the experimental measurements and allowed the simultaneous extraction of gain and RC information of the modules.
The second phase of the T2K experiment is expected to start data taking in autumn 2022. An upgrade of the Near Detector (ND280) is under development and includes the construction of two new Time ...Projection Chambers called High-Angle TPC (HA-TPC). The two endplates of these TPCs will be paved with eight Micromegas type charge readout modules. The Micromegas detector charge amplification structure uses a resistive anode to spread the charges over several pads to improve the space point resolution. This innovative technique is combined with the bulk-Micromegas technology to compose the "Encapsulated Resistive Anode Micromegas" detector. A prototype has been designed, built and exposed to an electron beam at the DESY II test beam facility. The data have been used to characterize the charge spreading and to produce a RC map. Spatial resolution better than 600 \(\mu\)m and energy resolution better than 9% are obtained for all incident angles. These performances fulfil the requirements for the upgrade of the ND280 TPC.
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it ...prevents cardiovascular events is uncertain.
We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years.
At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients 9.8% vs. 1563 patients 11.3%; hazard ratio, 0.85; 95% confidence interval CI, 0.79 to 0.92; P<0.001) and the key secondary end point (816 5.9% vs. 1013 7.4%; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter 1.9 mmol per liter). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%).
In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. (Funded by Amgen; FOURIER ClinicalTrials.gov number, NCT01764633 .).
PDF
